Sensorion SA (ALSEN.PA)
EUR 0.64
(-6.16%)
EUR 0.64
(-6.16%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.37 Million EUR | 472.7% |
| 2022 | -369.79 Thousand EUR | 95.37% |
| 2021 | -7.98 Million EUR | 82.74% |
| 2020 | -46.27 Million EUR | -937.5% |
| 2019 | -4.46 Million EUR | -65.18% |
| 2018 | -2.7 Million EUR | 62.59% |
| 2017 | -7.21 Million EUR | 4.39% |
| 2016 | -7.55 Million EUR | 37.44% |
| 2015 | -12.06 Million EUR | -10786.1% |
| 2014 | -110.85 Thousand EUR | -110.56% |
| 2013 | 1.04 Million EUR | 834.1% |
| 2012 | -142.95 Thousand EUR | -10.35% |
| 2011 | -129.54 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -85.69 Million EUR | 0.0% |
| 2023 Q4 | 1.37 Million EUR | 0.0% |
| 2023 Q2 | -11.23 Million EUR | 0.0% |
| 2023 FY | 1.37 Million EUR | 472.7% |
| 2022 Q4 | -369.79 Thousand EUR | 0.0% |
| 2022 Q2 | -20.2 Million EUR | 0.0% |
| 2022 FY | -369.79 Thousand EUR | 95.37% |
| 2021 Q4 | -7.98 Million EUR | 0.0% |
| 2021 FY | -7.98 Million EUR | 82.74% |
| 2021 Q2 | -7.15 Million EUR | 0.0% |
| 2020 Q2 | -23.73 Million EUR | 0.0% |
| 2020 FY | -46.27 Million EUR | -937.5% |
| 2020 Q4 | -46.27 Million EUR | 0.0% |
| 2019 Q2 | -2.36 Million EUR | 0.0% |
| 2019 Q4 | -4.46 Million EUR | 0.0% |
| 2019 FY | -4.46 Million EUR | -65.18% |
| 2018 FY | -2.7 Million EUR | 62.59% |
| 2018 Q2 | -8.79 Million EUR | 0.0% |
| 2018 Q4 | -2.7 Million EUR | 0.0% |
| 2017 Q2 | -4.51 Million EUR | 0.0% |
| 2017 FY | -7.21 Million EUR | 4.39% |
| 2017 Q4 | -5.35 Million EUR | 0.0% |
| 2016 Q2 | -8.5 Million EUR | 0.0% |
| 2016 Q4 | -7.65 Million EUR | 0.0% |
| 2016 FY | -7.55 Million EUR | 37.44% |
| 2015 FY | -12.06 Million EUR | -10786.1% |
| 2015 Q4 | -11.32 Million EUR | 0.0% |
| 2015 Q2 | -6.08 Million EUR | 0.0% |
| 2014 FY | -110.85 Thousand EUR | -110.56% |
| 2014 Q4 | -110.85 Thousand EUR | 0.0% |
| 2013 FY | 1.04 Million EUR | 834.1% |
| 2012 FY | -142.95 Thousand EUR | -10.35% |
| 2011 FY | -129.54 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 293.028% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 100.701% |
| Adocia SA | 127 Thousand EUR | -985.214% |
| Aelis Farma SA | -16.19 Million EUR | 108.512% |
| Biophytis S.A. | 2.7 Million EUR | 49.011% |
| Advicenne S.A. | 12.17 Million EUR | 88.68% |
| genOway Société anonyme | 2.97 Million EUR | 53.642% |
| IntegraGen SA | -709.74 Thousand EUR | 294.184% |
| Medesis Pharma S.A. | 1.15 Million EUR | -18.996% |
| Neovacs S.A. | -237.08 Thousand EUR | 681.315% |
| NFL Biosciences SA | -2.27 Million EUR | 160.558% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 68.364% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 265.941% |
| Theranexus Société Anonyme | 2.44 Million EUR | 43.612% |
| TME Pharma N.V. | -1.07 Million EUR | 227.731% |
| Valbiotis SA | -18.13 Million EUR | 107.598% |
| TheraVet SA | 12.78 Thousand EUR | -10679.992% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 36.779% |
| argenx SE | -1.83 Billion EUR | 100.075% |
| BioSenic S.A. | 28.04 Million EUR | 95.086% |
| Celyad Oncology SA | -6.1 Million EUR | 122.586% |
| DBV Technologies S.A. | -114.95 Million USD | 101.199% |
| Galapagos NV | -157.2 Million EUR | 100.877% |
| Genfit S.A. | -7.61 Million EUR | 118.108% |
| GeNeuro SA | 5.91 Million EUR | 76.681% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 105.488% |
| Innate Pharma S.A. | -30.71 Million EUR | 104.488% |
| Inventiva S.A. | 10.48 Million EUR | 86.86% |
| MaaT Pharma SA | -10.2 Million EUR | 113.505% |
| MedinCell S.A. | 39.5 Million EUR | 96.511% |
| Nanobiotix S.A. | -24.71 Million EUR | 105.576% |
| Onward Medical N.V. | -12.89 Million EUR | 110.689% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 3.643% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 94.92% |
| Oxurion NV | 10.71 Million EUR | 87.131% |
| Pharming Group N.V. | 99.4 Million EUR | 98.613% |
| Poxel S.A. | 44.55 Million EUR | 96.907% |
| GenSight Biologics S.A. | 16.29 Million EUR | 91.542% |
| Transgene SA | -14.4 Million EUR | 109.565% |
| Financière de Tubize SA | 78.62 Million EUR | 98.247% |
| UCB SA | 2.17 Billion EUR | 99.937% |
| Valneva SE | 82.73 Million EUR | 98.334% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 107.44% |